Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duramune is a veterinary vaccine line used primarily for the immunization of dogs against several major canine viral diseases. The most common formulations are combination vaccines containing modified live viruses for canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease), canine parainfluenza virus, and canine parvovirus. Some formulations also include killed or inactivated components such as canine coronavirus. The vaccine stimulates active immunity by exposing the animal’s immune system to antigens from these pathogens without causing disease. It is indicated for healthy dogs six weeks of age or older and is administered via subcutaneous injection[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Duramune.